SCHEDULE: Gilead Sciences Boosts Xilio Therapeutics Stake to 19.9%

Gilead Sciences, Inc. has disclosed a significant beneficial ownership stake of 19.9% in Xilio Therapeutics, Inc., holding over 10.6 million shares.

Summary

• Gilead Sciences, Inc. reported beneficial ownership of 10,613,944 shares of Xilio Therapeutics, Inc. common stock.
• This represents 19.9% of Xilio Therapeutics' outstanding common stock.
• The ownership includes 6,860,223 shares issued on March 28, 2024, 485,250 shares issued on April 3, 2024, and 1,759,978 shares issued on December 18, 2024.
• Additionally, the stake includes 1,508,493 shares issuable upon exercise of pre-funded warrants held by Gilead Sciences.
• The percentage is based on 51,827,910 shares of Xilio Therapeutics common stock issued and outstanding as of August 8, 2025, as reported in Xilio's Quarterly Report on Form 10-Q filed on August 14, 2025.
• Gilead Sciences, Inc. has sole voting and sole dispositive power over all 10,613,944 shares.
• The filing states the securities were not acquired or held for the purpose of changing or influencing control of Xilio Therapeutics, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant 19.9% stake by a major pharmaceutical company like Gilead Sciences in Xilio Therapeutics is generally viewed positively, as it implies confidence and potential strategic alignment. While a 13G is a factual disclosure, the implied endorsement from a large industry player can be a positive signal for the smaller company.

Positives

• A major pharmaceutical company like Gilead Sciences holding a significant stake (19.9%) in Xilio Therapeutics may signal confidence in Xilio's pipeline or strategic direction.
• Gilead's substantial investment could imply potential future collaboration or partnership opportunities, given its history in the biopharmaceutical sector.
• The accumulation of shares over several dates (March 28, 2024, April 3, 2024, December 18, 2024) suggests a sustained interest and commitment from Gilead.

Negatives

• A large beneficial ownership by a single entity, even if passive, could potentially limit the liquidity of Xilio's stock if Gilead were to divest a significant portion of its holdings.
• While the filing states no intent to control, a nearly 20% stake grants significant influence, which could lead to strategic decisions that may not align with all minority shareholders' interests.

Risks

• The value of Gilead's investment in Xilio Therapeutics is subject to the inherent risks of Xilio's business, including clinical trial outcomes, regulatory approvals, and market acceptance of its products.
• Future changes in Gilead's investment strategy or financial performance could lead to a reduction in its stake, potentially impacting Xilio's stock price.
• While the filing disclaims intent to control, a large shareholder could still exert influence through board nominations or other means, which might not always align with broader shareholder interests.

Future Outlook

Not applicable. This filing is a disclosure of current ownership, not forward-looking statements from the issuer or the reporting person regarding future performance or guidance.

Industry Context

In the biotechnology and pharmaceutical industry, a significant stake by a large, established player like Gilead Sciences in a smaller, clinical-stage company like Xilio Therapeutics can be interpreted as a strategic investment, potentially indicating interest in Xilio's therapeutic platforms or specific drug candidates. Such investments often precede or accompany collaboration agreements, licensing deals, or even future acquisition considerations, although this filing itself does not confirm such intentions. It signals a vote of confidence from a major industry participant.

Comparison to Industry Standards

• A 19.9% stake is a substantial minority interest, placing Gilead Sciences as a significant shareholder in Xilio Therapeutics. While not a controlling stake (which would typically be 50% or more), it is large enough to warrant close attention from other investors.
• Similar large minority investments have been seen in the biotech sector where larger pharmaceutical companies invest in smaller innovative firms, such as Pfizer's investments in various biotech startups or Merck's strategic equity stakes in companies developing complementary technologies.
• This level of ownership often grants the investor significant influence, potentially including board representation or preferential access to future developments, even if control is disclaimed.

Related Party Transactions

• The acquisition of 10,613,944 shares of Xilio Therapeutics by Gilead Sciences, Inc. could be considered a related party transaction if there is a pre-existing strategic partnership or agreement between the two entities that led to these share issuances and warrant holdings. The filing itself does not explicitly label it as such but details the direct issuance of shares to Gilead.

Stakeholder Impact

• Shareholders: Existing shareholders may view Gilead's significant stake as a positive indicator of Xilio's potential, potentially leading to increased investor confidence and stock price appreciation. However, a large concentrated ownership could also reduce liquidity or influence future strategic decisions.
• Employees: A strong strategic investor like Gilead could provide stability and resources, potentially benefiting employees through continued operations and growth opportunities.
• Customers/Partners: While not directly impacted by ownership disclosure, a strong financial backing from Gilead could enhance Xilio's credibility and attractiveness for future collaborations or customer relationships.

Key Dates

Recommendation

The filing indicates a significant strategic investment by Gilead Sciences in Xilio Therapeutics, which is generally a positive signal for the smaller company's prospects. However, a Schedule 13G primarily discloses ownership and does not provide financial performance data, operational updates, or future guidance from Xilio Therapeutics itself. Therefore, while the large stake by Gilead is noteworthy and suggests potential long-term value, a 'hold' recommendation is appropriate as further fundamental analysis of Xilio's financials, pipeline, and market position is required for a stronger investment stance.

Keywords

Xilio Therapeutics, Gilead Sciences, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Pharmaceuticals, Investment, Stake